{"gold_plan":"化疗\n西药及中成药方：※[甲]注射用重组人粒细胞刺激因　100ug×2支/皮下　1支/qd　d1,2。本科处置：肌肉注射×2次检验科申请：血常规新(五分类)检查地点：徐汇院区：东安路270号1号楼3楼检验科 。","meta_info":"342322196506070041","patient_id":"342322196506070041","Time":"2023-01-03 08:53:53.233000","question":{"CASE_CORE":{"VISIT_DATE":"2023-01-03","last_platinum_end_date":"2022-11-26","first_relapse_date":"2022-07-24","PFI_days":"181","PLATINUM_STATUS":"Unknown","PLATINUM_STATUS_CURRENT":"Unknown","PLATINUM_PFI_CURRENT":"Unknown","SCENE":"Platinum_sensitive_recurrence","PLATINUM_HISTORY":[{"line":"1L","start_date":"Unknown","end_date":"2022-01-24","first_relapse_date":"2022-07-24","PFI_days":"181","status":"Sensitive","evidence_type":"Biochemical","evidence":"CA125 31.9 on 2022-07-24"},{"line":"2L","start_date":"2022-08","end_date":"2022-08","first_relapse_date":"Unknown","PFI_days":"Unknown","status":"Unknown","evidence_type":"Radiologic","evidence":"PET 2022-08-19: pelvic/mesenteric FDG-avid lesions; CA125 rise in Aug 2022"},{"line":"3L","start_date":"2022-09-22","end_date":"2022-11-26","first_relapse_date":"Unknown","PFI_days":"Unknown","status":"Unknown","evidence_type":"Biochemical","evidence":"CA125 349 on 2022-09-14; multiple subsequent CA125 measurements"}],"DIAGNOSIS":{"primary":"Ovarian malignant tumor","histology":"高级别浆液性癌","site":"Ovary","laterality":"Bilateral","components":[]},"STAGE":{"stage_text":"Unknown","stage_system":"Unknown","stage_basis":"Pathology"},"INITIAL_TREATMENT":"Yes","SURGERY_DONE":{"performed":"Yes","date":"2021-09-08","procedure":"Modified radical hysterectomy + bilateral salpingo-oophorectomy + pelvic peritoneal resection + omentectomy + splenectomy + partial diaphragm resection + appendectomy + tumor debulking + complex enteric adhesiolysis"},"NEOADJUVANT":"Unknown","ADJUVANT_TREATMENT":{"given":"Yes","regimens":["白紫+卡铂"],"cycles_or_courses":"7"},"LINE_OF_THERAPY":[{"line":"1L","intent":"Adjuvant","regimen":"白紫+卡铂","start_date":"Unknown","end_date":"2022-01-24","cycles":"7"},{"line":"2L","intent":"Unknown","regimen":"紫杉醇+卡铂","start_date":"2022-08","end_date":"2022-08","cycles":"1"},{"line":"3L","intent":"Unknown","regimen":"异环磷酰胺+依托泊苷+贝伐 (+顺铂 added 2022-10-13)","start_date":"2022-09-22","end_date":"2022-11-26","cycles":"Unknown"}],"MAINTENANCE":"Yes","MAINTENANCE_DETAIL":{"given":"Yes","regimens":["尼拉"],"start_date":"2022-02","end_date":"2022-07"},"RELAPSE":"Yes","RELAPSE_DATE":{"date":"2022-07-24","type":"Biochemical","evidence":"CA125 31.9 on 2022-07-24"},"HRD":"Negative","BRCA1":"Wildtype","BRCA2":"Wildtype","BIOMARKERS":{"TMB":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","HER2":"Unknown","AFP":"1.05 ng/ml (2022-01-17)","CA125":"90.50 U/ml (2022-12-12)"},"CURRENT_STATUS":"Post extensive debulking surgery; multiple lines of chemotherapy completed; last chemotherapy 2022-11-26; ongoing surveillance as of 2023-01-03."},"TIMELINE":{"events":[{"date":"2021-08-27","event_type":"Lab","description":"Initial tumor markers at outside hospital","regimen_or_test":"CA125, HE4, CA15-3","key_result":"CA125 600+, HE4 421, CA15-3 82"},{"date":"2021-09-08","event_type":"Surgery","description":"Extensive cytoreductive surgery performed","regimen_or_test":"Modified radical hysterectomy + bilateral adnexectomy + multiple resections","key_result":"Specimens positive for metastatic disease; high-grade serous carcinoma"},{"date":"2021-09-16","event_type":"Chemo","description":"Postoperative platinum-based chemotherapy started","regimen_or_test":"白紫+卡铂","key_result":"Planned 7 cycles, last 2022-01-24"},{"date":"2021-09-28","event_type":"Lab","description":"Postoperative tumor markers","regimen_or_test":"CA125 etc","key_result":"CA125 1305.00 U/ml"},{"date":"2022-07-24","event_type":"Lab","description":"Biochemical evidence of relapse","regimen_or_test":"CA125","key_result":"CA125 31.9"},{"date":"2022-08-19","event_type":"Imaging","description":"FDG PET/CT after relapse","regimen_or_test":"FDG-PET/CT","key_result":"Pelvic/mesenteric metastases FDG-avid involving sigmoid colon"},{"date":"2022-09-22","event_type":"Chemo","description":"Salvage chemotherapy initiated","regimen_or_test":"异环磷酰胺+依托泊苷+贝伐","key_result":"Regimen given from 2022-09-22; later added 顺铂 on 2022-10-13"},{"date":"2022-11-26","event_type":"Chemo","description":"Last documented chemotherapy visit","regimen_or_test":"异环磷酰胺+依托泊苷+贝伐+顺铂","key_result":"Last chemotherapy given 2022-11-26"},{"date":"2022-02","event_type":"Other","description":"Oral maintenance started","regimen_or_test":"尼拉","key_result":"Niraparib from 2022-02 to 2022-07"}],"constraints":{"min_events":3,"max_events":30,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}}},"MED_ONC":{"current_regimen":{"name":"Unknown","last_admin_date":"2022-11-26","cycle_info":"Unknown"},"planned_next_regimen":"Unknown","prior_systemic_therapies":["白紫+卡铂","紫杉醇+卡铂","异环磷酰胺+依托泊苷+贝伐 (+顺铂)"],"genetic_testing":{"somatic":["HRD: Negative","BRCA1: Wildtype","BRCA2: Wildtype"],"germline":["HRD: Negative","BRCA1: Wildtype","BRCA2: Wildtype","BLM c.3925delA p.R1309Efs*97 (suspected germline)"]},"monitoring_points":[{"drug_or_class":"PARP inhibitor (尼拉)","monitoring":["Monitor tumor markers (CA125)","Monitor blood counts and organ function"]}]},"RADIOLOGY":{"studies":[{"date":"2021-08-30","modality":"Other","anatomic_sites":["Omentum","Rectouterine pouch","Abdomen/pelvis"],"findings":["Multiple hypermetabolic nodules in omentum and rectouterine pouch; abdominal and pelvic ascites; tuberculosis not excluded"],"impression":"Hypermetabolic omental and pelvic nodules; ascites; TB not excluded","trend_vs_prior":"Unknown"},{"date":"2022-01-03","modality":"CT","anatomic_sites":["Pelvis","Abdomen"],"findings":["Postoperative changes after ovarian cancer surgery; several small retroperitoneal lymph nodes; liver cyst; renal cysts and stones"],"impression":"Postoperative changes, follow-up recommended","trend_vs_prior":"Unknown"},{"date":"2022-08-19","modality":"Other","anatomic_sites":["Pelvis","Mesentery","Sigmoid colon"],"findings":["Postoperative chemotherapy case with possible pelvic mesenteric metastases; FDG uptake increased, may involve sigmoid colon"],"impression":"Possible pelvic/mesenteric metastases with increased FDG uptake","trend_vs_prior":"Worse"}],"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"}},"PATHOLOGY":{"specimens":[{"date":"2021-09-08","site":"Ovary and multiple peritoneal sites","diagnosis":"高级别浆液性癌","components":["Uterus","Bilateral adnexa","Pelvic peritoneum","Omentum","Appendix","Spleen","Various peritoneal/mesenteric nodules"],"grade":"Unknown","tumor_size":"Left ovary 1.7×1.2×1.9 cm; Right ovary 2.5×1.1×1.1 cm","laterality":"Bilateral","sample_type":"Surgical resection specimens","involvement_sites":["Left and right fallopian tubes (tumor involvement)","Peritoneum (multiple sites)","Omentum (infiltrative metastatic adenocarcinoma)","Appendix (involved)"],"ihc":[{"marker":"P53","result":"+"},{"marker":"WT1","result":"+"},{"marker":"CK7","result":"+"},{"marker":"ER","result":"+"},{"marker":"P16","result":"+"},{"marker":"PAX8","result":"+"},{"marker":"AE1/AE3","result":"+"},{"marker":"Vimentin","result":"-"}],"molecular":[],"raw_text":"Specimens: sub-extensive uterus + bilateral adnexa + pelvic peritoneum + omentum + appendix, spleen. Tumor sizes: left 1.7×1.2×1.9 cm; right 2.5×1.1×1.1 cm. Bilateral ovaries. Pathology: high-grade serous carcinoma. Multiple pelvic/abdominal sites positive for carcinoma. Omentum shows infiltrative/metastatic adenocarcinoma consistent with high-grade serous carcinoma. IHC: P53(+), WT1(+), CK7(+), ER(+), P16(+), PAX8(+), AE1/AE3(+), Vimentin(-).","uncertainty_or_missing":["Exact FIGO stage not provided","Molecular testing not detailed in this specimen report"]}]},"NUC_MED":{"studies":[{"date":"2022-08-19","type":"FDG-PET/CT","avid_lesions":["Pelvic/mesenteric metastases involving sigmoid colon"],"non_avid_notes":["Left maxillary sinus and right upper lung chronic inflammation noted"],"confidence":"Moderate"}]},"LAB_TRENDS":{"labs":[{"analyte":"CA125","unit":"U/ml","reference_range":"Unknown","latest":{"date":"2022-12-12","value":"90.50","flag":"↑"},"history":[{"date":"2021-08-27","value":"600+","flag":"↑"},{"date":"2021-09-28","value":"1305.00","flag":"↑"},{"date":"2021-10-26","value":"117.00","flag":"↑"},{"date":"2021-11-15","value":"37.60","flag":"↑"},{"date":"2021-12-06","value":"20.20","flag":"Unknown"},{"date":"2021-12-27","value":"15.00","flag":"Unknown"},{"date":"2022-01-17","value":"10.80","flag":"Unknown"},{"date":"2022-02-09","value":"12.10","flag":"Unknown"},{"date":"2022-06-15","value":"10.10","flag":"Unknown"},{"date":"2022-07-24","value":"31.9","flag":"Unknown"},{"date":"2022-08-16","value":"199.00","flag":"↑"},{"date":"2022-08-24","value":"261.00","flag":"↑"},{"date":"2022-09-14","value":"349.00","flag":"↑"},{"date":"2022-10-06","value":"310","flag":"↑"},{"date":"2022-10-31","value":"150.00","flag":"↑"},{"date":"2022-11-21","value":"118.00","flag":"↑"},{"date":"2022-12-12","value":"90.50","flag":"↑"}]}],"milestones":[{"date":"2021-09-08","type":"Surgery","description":"Extensive cytoreductive surgery"},{"date":"2021-09-16","type":"ChemoStart","description":"Start postoperative 白紫+卡铂 chemotherapy"},{"date":"2022-01-24","type":"ChemoEnd","description":"Last cycle of initial adjuvant chemotherapy"},{"date":"2022-07-24","type":"Relapse","description":"Biochemical relapse with CA125 rise"},{"date":"2022-11-26","type":"ChemoEnd","description":"Last documented chemotherapy"}]}},"question_raw":"卵巢恶性肿瘤：流调否认中高风险地区旅居史，否认体温异常等新冠肺炎症状。复测华大基因检测：疑似胚系突变BLM c.3925delA p.R1309Efs*97盆腔肿瘤：2021.8.27 CA125 600+ HE4 421 CA153 82胸水：癌细胞2021.8.30 PET：大网膜 子宫直肠陷凹多发高代谢结节，腹盆腔积液，结核不除外；胃镜无明显异常母亲卵巢癌 姐姐乳腺癌 妹妹卵巢癌2021.09.08在全身麻醉下,行改良子宫根治性切除术+双附件切除术+盆底腹膜切除术+大网膜切除术+脾切除术+膈肌部分切除术+阑尾切除术+瘤体减灭术+复杂肠粘连松解术，术后病理：标本类型:次广泛子宫+双附件+盆底腹膜+大网膜+阑尾、脾脏肿瘤大小:左侧：1.7×1.2 ×1.9 cm；右侧：2.5×1.1 ×1.1 cm肿瘤侧别:双侧卵巢病理类型:高级别浆液性癌其他部位情况:左输卵管:见癌累及右输卵管:见癌累及子宫内膜:萎缩改变宫颈:慢性炎子宫肌层:平滑肌瘤（1枚，直径0.3 cm）盆腹腔多部位病灶:（盆底腹膜、大网膜、肝膈肌肿瘤及肝肾隐窝肿瘤、阑尾、左侧结肠旁沟腹膜、右侧结肠旁沟腹膜、降结肠系膜结节）见癌累及；其他:（脾脏）未见特殊（大网膜）见浸润/转移性腺癌，需待免疫组化辅助分型。补充报告：（大网膜）见浸润/转移性腺癌，需待结合免疫组化结果，符合高级别浆液性癌。注：免疫组化结果（HI21-21955）：肿瘤细胞P53（+），WT1（+），CK7（+），ER（+），P16（+），PAX8（+），AE1/AE3（+），Vimentin（-）2021.09.28：CA19-9:7.35U/ml,CA125:1305.00U/ml↑,CA15-3:49.90U/ml↑,AFP:1.19ng/ml,CEA:1.63ng/ml,HE4:164.00pmol/L↑,ROMA:64.26%(绝经前)↑,ROMA.:92.17%(绝经后)↑2021.09.16 术后白紫+卡铂化疗7程，末次2022.1.24基因检测：HRD-；BRCA-2021.10.26：CA125:117.00U/ml↑血常规、肝肾功能一般可东院肿瘤标志物（2021.11.15）：CA125:37.60U/ml↑。2021.12.06：CA125:20.20U/ml,CA15-3:14.10U/ml,HE4:69.20pmol/L,ROMA:15.09%(绝经前)↑,ROMA.:18.49%(绝经后)2021.12.27：CA125:15.00U/ml,HE4:58.50pmol/L,ROMA:10.47%(绝经前),ROMA.:13.29%(绝经后)肿瘤标志物（2022.01.17）：CA19-9:9.09U/ml,CA125:10.80U/ml,CA15-3:10.80U/ml,AFP:1.05ng/ml,CEA:1.62ng/ml,HE4:59.90pmol/L,ROMA:10.81%(绝经前),ROMA.:10.99%(绝经后)。口服CT（2022.01.03）：腹膜后数枚小淋巴结，随访。肝尾叶囊肿，左肾小结石，左肾数枚小囊肿。MR（2022.01.03）：卵巢癌术后改变，请随访。2022.02.09：CA125:12.10U/ml,CA15-3:8.21U/ml,CEA:1.67ng/ml,HE4:61.50pmol/L,ROMA:11.50%(绝经前)↑,ROMA.:12.12%(绝经后)2022.06.15 CA125：9.62022.06.15 CA125：10.10;HE4：60.52022.04.19 外院MRI;盆腔内及两侧腹股沟区多发小淋巴结；2022.04.19 外院CT:盆腹腔无殊2022.02开始口服尼拉至2022.72022.07.24 CA125：31.9;HE4：75;CA199：10.7;2022.08.16：CA19-9:9.49U/ml,CA125:199.00U/ml↑,CEA:3.66ng/ml核医学报告（2022.08.19）：1.卵巢癌术后化疗后，盆腔肠系膜转移可能，累及乙状结肠，FDG代谢增高。 2.左侧上颌窦、右上肺慢性炎症；左肾小囊肿；T11-12退变；腹壁切口疝。2022.08.24：CA19-9:10.10U/ml,CA125:261.00U/ml↑,CEA:3.22ng/ml血常规 肝肾可2022.8. 紫杉醇+卡铂化疗1程2022.09.14：CA125:349.00U/ml↑,HE4:127.00pmol/L↑,ROMA:47.39%(绝经前)↑,ROMA.:77.45%(绝经后)↑肝肾 血常规可2022.09.22 异环磷酰胺+依托泊苷+贝伐化疗1程2022.10.06 CA125:3102022.10.10 血常规、肝肾功能一般可2022.10.13 异环磷酰胺+依托泊苷+贝伐+顺铂化疗1程2022.10.31：CA125:150.00U/ml↑2022.10.31 血常规：RBC(红细胞计数):2.96*10^12/L↓，HGB(血红蛋白):99g/l↓，肝肾功能一般可肿瘤标志物（2022.11.21）：CA125:118.00U/ml↑。2022.11.21 血常规：白细胞5.0,血红蛋白102↓.血小板367↑末次化疗11.26异环磷酰胺+依托泊苷+贝伐+顺铂化疗1程2022.12.12：CA125:90.50U/ml↑2022.12.12 血常规预约第7次化疗"}
